Physician profile
John N Soltys
NPI 1194221952
$3,974.33
in general payments reported to CMS, 2019-2025
40 companies · $1,969 in 2025
The $1,969 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $136 · 2020: $162 · 2021: $537 · 2022: $348 · 2024: $822 · 2025: $1,969.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,791.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,791.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $403.73 | 2021-2025 | Ultomiris |
| Eisai INC. | $333.45 | 2021-2025 | |
| Ucb, INC. | $312.71 | 2022-2025 | Rystiggo, Briviact, Fintepla |
| Novartis Pharmaceuticals Corporation | $300.63 | 2024-2025 | |
| Amgen INC. | $212.61 | 2022-2025 | Uplizna |
| Jazz Pharmaceuticals INC. | $211.08 | 2022-2025 | |
| Acadia Pharmaceuticals INC | $205.88 | 2021-2025 | Nuplazid, Daybue |
| Sk Life Science, INC. | $190.35 | 2024-2025 | |
| Acorda Therapeutics, INC | $172.47 | 2019-2022 | |
| Lundbeck LLC | $144.38 | 2020-2025 | Vyepti |
| Genentech USA, INC. | $142.61 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Genentech, INC. | $113.53 | 2024 | Ocrevus, Ocrevus Zunovo |
| Argenx US, INC. | $83.39 | 2024-2025 | Vyvgart Hytrulo |
| Emd Serono, INC. | $83.08 | 2022-2025 | |
| Biogen, INC. | $76.33 | 2021-2022 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $73.03 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $66.86 | 2024-2025 | Hyqvia |
| Merz Pharmaceuticals, LLC | $63.25 | 2024-2025 | Xeomin |
| Supernus Pharmaceuticals, INC. | $58.71 | 2019-2021 | |
| Janssen Biotech, INC. | $58.54 | 2025 | Tremfya |
| Lilly USA, LLC | $57.76 | 2019-2025 | Emgality, Amyvid, Kisunla |
| Neurocrine Biosciences, INC. | $56.70 | 2025 | |
| Adamas Pharmaceuticals, INC. | $55.77 | 2019-2020 | |
| Upsher-Smith Laboratories LLC | $54.07 | 2021-2025 | |
| Tanabe Pharma America, INC. | $49.39 | 2021-2024 | |
| Vanda Pharmaceuticals INC. | $47.96 | 2025 | Ponvory |
| Allergan, INC. | $46.59 | 2021 | |
| Abbvie INC. | $37.36 | 2022 | |
| Axsome Therapeutics, INC. | $33.24 | 2025 | Symbravo |
| Ani Pharmaceuticals, INC. | $31.11 | 2024 | Purified Cortrophin Gel |
| Alnylam Pharmaceuticals INC. | $27.36 | 2025 | Amvuttra |
| Grifols USA, LLC | $25.01 | 2024 | Gamunex-C |
| Mallinckrodt Hospital Products INC. | $20.03 | 2025 | Acthar |
| Neurelis, INC. | $20.02 | 2024 | Valtoco |
| Akcea Therapeutics, INC. | $19.48 | 2019 | |
| Tg Therapeutics, INC. | $19.19 | 2025 | |
| Kedrion Biopharma, INC. | $17.79 | 2025 | Kedrab, Albuked, Rhogam Ultra-Filtered Plus |
| Csl Behring | $16.94 | 2019 | |
| Chiesi USA, INC. | $16.31 | 2022 | |
| Pfizer INC. | $15.63 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Soltys listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.